Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate Journal Article

  


Authors: Scher, H. I.; Yagoda, A.; Ahmed, T.; Watson, R. C.
Article Title: Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate
Abstract: Methylglyoxal-bis(guanylhydrazone) (MGBG), an inhibitor of polyamine synthesis, was administered to 35 patients with hormone-resistant advanced adenocarcinoma of the prostate in doses of 500 or 600 mg/m2 per week intravenously. Of 31 patients with bidimensionally measurable soft-tissue lesions, 25 had an adequate trial, defined as four or more doses. Six (24%; 95% confidence limits, 8% to 32%) patients achieved a partial remission (≥ 50% reduction in tumor size) in soft-tissue disease. Response was noted to start after one to two doses and persisted for a median of three months (range, 1 to 4 months). Toxicity was tolerable, and significant myelosuppression was not observed. The lack of response in osseous metastases may be secondary to the short duration of remission or to the presence or inducibility of the enzyme ornithine decarboxylase in bone. Since some animal prostatic cancer tumor models are sensitive to cytotoxic drugs that produce polyamine inhibition, clinical trials of MGBG combined with other inhibitors of the polyamine pathway should be explored.
Keywords: cancer chemotherapy; clinical article; drug efficacy; bone metastasis; mucosa inflammation; nausea; vomiting; myalgia; gastrointestinal toxicity; bone; muscle weakness; drug therapy; adverse drug reaction; therapy; intravenous drug administration; prostate carcinoma; mitoguazone; muscle; bone marrow depression; intoxication; male genital system; human; priority journal; polyamine synthesis; blood and hemopoietic system
Journal Title: Journal of Clinical Oncology
Volume: 3
Issue: 2
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 1985-02-01
Start Page: 224
End Page: 228
Language: English
DOI: 10.1200/jco.1985.3.2.224
PROVIDER: scopus
PUBMED: 3968552
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021954259&doi=10.1200%2fJCO.1985.3.2.224&partnerID=40&md5=d920dee90cec79996b6020f798cb962b
Notes: Article -- Export Date: 26 October 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Howard Scher
    1130 Scher
  2. Alan Yagoda
    51 Yagoda
  3. Robin Caird Watson
    25 Caird Watson
Related MSK Work